In the critical situation that arose from coronavirus pandemic, every country with its team of researchers is trying to develop a vaccine for the global concern of COVID 19.
A bunch of researchers at Hansraj College, Delhi University has announced that they have developed a novel drug molecule with great potential to decrease the effects of this fatal virus.
The team headed by Brijesh Rathi, instead of blindly screening the molecules (which is time-consuming and relatively costly), the researchers have done in-silicon studies.
Thereafter, the testing was performed in Loyola University, Chicago, and the University of New Mexico, the USA in order against SARS- CoV – 2 in culture.
The Chief of the team, Rathi is an assistant professor in the Department of Chemistry at Hansraj College, Delhi University. He pursued a Ph.D. from MIT, Cambridge University.
US Provisional Patent The application was filed jointly by Rathi and his associate collaborators, which includes Professor Ravi Durvasa, and Dr. P Kempaiah from Loyola University Chicago and Dr. Steven Bradfute from the University of New Mexico, the USA stating “Calxinin Compositions and Method for Treating Viral Infections”.
After this, subsequent negotiations have been done with Redcliffe Bioscience, UK the located company, so that they could have clinical testing of Calxinin in the lab. The team is quite hopeful for the success of this drug, which would shortly kick out the deadly virus from the world.
Redcliffe Bioscience will conduct a clinical examination handed out a letter of purpose on May 29.
The pharmacy company asserted “This Letter of Purpose is constructed to enable an alliance with Hansraj College (University of Delhi), Loyola University Chicago and University of New Mexico, USA. Our UK-based company ‘Redcliffe Bioscience Ltd’ is in treaty with these signees to take their labeled recent antiviral molecule (named as ‘Calxinin’) for the clinical session and to formulate it as an anti-coronavirus drug at the quick mode.”
They further added, “ We also determined to form a reliable new special purpose vehicle (SPV) entity Future Therapeutic Ltd in London for checking our COVID-affiliated lab research.”
“We are devoted to take this conceivable molecule developed at these above universities to animal level effectiveness and toxicity testing. Our company with other colleges would be pleased to join hands together and create a drug against COVID 19,” the company further contended.
The head asserted that the team has completed the initial tests of the molecule. We have secured with Redcliffe Bioscience to find a medication and it has conceded to put this further for clinical reviews at the rapid possible speed. We have confronted half the challenge and anticipate the remaining half to be successfully marketed by the company as soon as possible.”
By the time, The Indian Council of Medical Research is assisting private and public laboratories to conduct various experiments related to COVID 19 by giving them approval.
A total of 681 laboratories within India have been given permission to conduct the examination for Covid-19. These include 476 union laboratories and 205 private laboratories.
The ICMR disclosed that an aggregate of one lakh 28 thousand 868 samples of Coronavirus was assessed in the last 24 hours. With this, the total number of tryouts sums up 39,66,075 in the country.